October 14, 2026
A D.C. federal judge has enforced a nearly $18 million arbitral award against Novartis Pharma AG following its dispute with biotechnology firm Genentech Inc. over a licensing agreement for an eye medication.
June 06, 2025
California-based biotech firm Genentech Inc. has asked a D.C. federal court to recognize a $17.8 million arbitral award against Novartis Pharma AG stemming from a dispute over a licensing agreement for an eye medication.